SAN MATEO, Calif., March 30, 2011 /PRNewswire/ — Nile
Therapeutics, Inc. (Nasdaq:
NLTX), a biopharmaceutical company that develops novel
therapeutics for heart failure patients, today announced the
schedule of its upcoming cenderitide presentation taking place at
the American College of Cardiology (ACC) 60th Scientific Session,
April 2-5th.

Location: Ernest N. Morial Convention Center, Hall F

Date: Sunday, April 3, 2011

Time: 10:00 AM -11:15 AM (CDT)

Poster Presentation: Board #256

Presenter: Hsiao D. Lieu, MD, FACC

Title: “A Phase II, Dose-Ranging Study with CD-NP, a Chimeric
Natriuretic Peptide, in Acute Decompensated Heart Failure Patients
with Renal Compromise”

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical
company that develops innovative products for the treatment of
cardiovascular disease and other areas of unmet medical needs. Nile
is initially focusing its efforts on developing its lead compound,
cenderitide, a novel rationally designed chimeric peptide in
clinical studies for the treatment of heart failure, and CU-NP, a
novel rationally designed natriuretic peptide. More information on
Nile can be found at http://www.nilethera.com.

‘/>”/>

SOURCE